Martin David Harp

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Conavi leverages ophthalmic imaging technology to enhance intravascular diagnostics in cardiology.

The partnership was announced in August of this year.

OKYO Pharma advances urcosimod for neuropathic corneal pain, targeting a new clinical trial to optimize treatment and registration pathways.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

IVMED-85 is a preservative-free prescription eye drop designed to prevent myopia progression in children.

We ask leading experts in the field what eye disease they would cure and why.

We ask leading experts in the field what eye disease they would cure and why.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the Centurion Vision System with Active Sentry.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

We ask leading experts in the field what eye disease they would cure and why.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

We ask leading experts in the field what eye disease they would cure and why.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.

Wavelight plus was first launched in China, with several European and Asia-Pacific markets following suit

We ask leading experts in the field what eye disease they would cure and why.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

Phentolamine ophthalmic solution 0.75% is for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

The start of the series that asks leading experts in the field what eye disease they would cure and why.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

This marks the first time that the TearCare System has been included in the TFOS DEWS III Management and Therapy Report.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).